EUR 53.4
(2.5%)
Year | Net Income | Net Income Growth |
---|---|---|
2023 | 75.79 Million EUR | 110.59% |
2022 | 35.99 Million EUR | 370.82% |
2021 | -13.29 Million EUR | -124.28% |
2020 | -5.92 Million EUR | -158.39% |
2019 | -2.29 Million EUR | -132.31% |
2018 | 7.09 Million EUR | 548.89% |
2017 | -1.58 Million EUR | 61.11% |
2016 | -4.06 Million EUR | -804.07% |
2015 | 577.51 Thousand EUR | -32.87% |
2014 | 860.32 Thousand EUR | 111.11% |
2013 | -7.74 Million EUR | -223.17% |
2012 | -2.39 Million EUR | -85.68% |
2011 | -1.29 Million EUR | -27.84% |
2010 | -1 Million EUR | -428.3% |
2009 | -191 Thousand EUR | 0.0% |
Year | Net Income | Net Income Growth |
---|---|---|
2024 Q2 | -10.09 Million EUR | 0.0% |
2023 Q2 | 1.8 Million EUR | 0.0% |
2023 Q4 | 73.99 Million EUR | 0.0% |
2023 FY | 75.79 Million EUR | 110.59% |
2022 FY | 35.99 Million EUR | 370.82% |
2022 Q2 | 80.03 Million EUR | 0.0% |
2022 Q4 | -44.03 Million EUR | 0.0% |
2021 Q2 | -10.17 Million EUR | 0.0% |
2021 Q4 | -3.3 Million EUR | 0.0% |
2021 FY | -13.29 Million EUR | -124.28% |
2020 Q4 | -4.54 Million EUR | 0.0% |
2020 FY | -5.92 Million EUR | -158.39% |
2020 Q2 | -1.38 Million EUR | 0.0% |
2019 Q2 | -695.02 Thousand EUR | 0.0% |
2019 FY | -2.29 Million EUR | -132.31% |
2019 Q4 | -1.59 Million EUR | 0.0% |
2018 Q4 | -490.17 Thousand EUR | 0.0% |
2018 Q2 | 7.58 Million EUR | 0.0% |
2018 FY | 7.09 Million EUR | 548.89% |
2017 Q4 | 1.32 Million EUR | 0.0% |
2017 FY | -1.58 Million EUR | 61.11% |
2017 Q2 | -2.9 Million EUR | 0.0% |
2016 FY | -4.06 Million EUR | -804.07% |
2016 Q2 | -1.18 Million EUR | 0.0% |
2016 Q4 | -2.88 Million EUR | 0.0% |
2015 Q4 | -951.17 Thousand EUR | 0.0% |
2015 Q2 | 1.52 Million EUR | 0.0% |
2015 FY | 577.51 Thousand EUR | -32.87% |
2014 FY | 860.32 Thousand EUR | 111.11% |
2014 Q4 | -1.64 Million EUR | 0.0% |
2014 Q2 | 2.5 Million EUR | 0.0% |
2013 Q3 | -1.93 Million EUR | 0.0% |
2013 FY | -7.74 Million EUR | -223.17% |
2013 Q4 | 215.08 Thousand EUR | 111.11% |
2013 Q2 | -1.93 Million EUR | 0.0% |
2013 Q1 | -1.93 Million EUR | 0.0% |
2012 Q3 | -598.8 Thousand EUR | 0.0% |
2012 Q1 | -598.8 Thousand EUR | 0.0% |
2012 Q4 | -1.93 Million EUR | -223.17% |
2012 Q2 | -598.8 Thousand EUR | 0.0% |
2012 FY | -2.39 Million EUR | -85.68% |
2011 Q2 | -323.75 Thousand EUR | 0.0% |
2011 Q1 | -323.75 Thousand EUR | 0.0% |
2011 FY | -1.29 Million EUR | -27.84% |
2011 Q3 | -323.75 Thousand EUR | 0.0% |
2011 Q4 | -598.8 Thousand EUR | -84.96% |
2010 Q1 | -252.26 Thousand EUR | 0.0% |
2010 FY | -1 Million EUR | -428.3% |
2010 Q4 | -323.75 Thousand EUR | -28.34% |
2010 Q3 | -252.26 Thousand EUR | 0.0% |
2010 Q2 | -252.26 Thousand EUR | 0.0% |
2009 Q4 | -252.26 Thousand EUR | -428.3% |
2009 Q2 | -47.75 Thousand EUR | 0.0% |
2009 Q1 | -47.75 Thousand EUR | 0.0% |
2009 Q3 | -47.75 Thousand EUR | 0.0% |
2009 FY | -191 Thousand EUR | 0.0% |
2008 Q4 | -47.75 Thousand EUR | 0.0% |
Name | Net Income | Net Income Difference |
---|---|---|
BioNTech SE | 930.3 Million EUR | 91.853% |
CureVac N.V. | -260.16 Million EUR | 129.133% |
Biotest Aktiengesellschaft | 127 Million EUR | 40.319% |
Biotest Aktiengesellschaft | 127 Million EUR | 40.319% |
BRAIN Biotech AG | -8.27 Million EUR | 1015.509% |
Heidelberg Pharma AG | -20.34 Million EUR | 472.521% |
Medigene AG | -16.17 Million EUR | 568.536% |